|
US6756038B1
(en)
*
|
1997-10-10 |
2004-06-29 |
The United States Of America As Represented By The Department Of Health And Human Services |
Agonist and antagonist peptides of carcinoembryonic antigen (CEA)
|
|
WO2001024832A2
(de)
*
|
1999-09-27 |
2001-04-12 |
Gabriele Pecher |
Pharmazeutische zusammensetzung zur behandlung und prophylaxe von humanen tumoren, die das tumorantigen muzin und/oder das carcinoembryonale antigen (cea) exprimieren und ihre verwendung
|
|
EP1227837B1
(en)
*
|
1999-10-22 |
2008-05-21 |
Aventis Pasteur Limited |
Method of inducing and/or enhancing an immune response to tumor antigens
|
|
US7179462B2
(en)
|
2000-06-02 |
2007-02-20 |
University Of Connecticut Health Center |
α (2) macroglobulin receptor as a heat shock protein receptor and uses thereof
|
|
JP2004505894A
(ja)
|
2000-06-02 |
2004-02-26 |
ユニバーシティー オブ コネティカット ヘルス センター |
免疫療法のためのα（２）マクログロブリンと抗原分子との複合体
|
|
US7186515B1
(en)
|
2000-06-02 |
2007-03-06 |
University Of Connecticut Health Center |
Alpha(2) macroglobulin receptor as a heat shock protein receptor and uses thereof
|
|
AU2001278330A1
(en)
*
|
2000-07-31 |
2002-02-13 |
Aventis Pasteur Limited |
Modified CEA and uses thereof
|
|
EP1350113A2
(en)
|
2000-08-30 |
2003-10-08 |
Chemocentryx, Inc. |
Inhibition of cmv infection and dissemination
|
|
US7820441B2
(en)
|
2000-09-25 |
2010-10-26 |
The Regents Of The University Of Michigan |
Production of viral vectors
|
|
CA2437201C
(en)
|
2001-02-02 |
2008-11-18 |
Chemocentryx, Inc. |
Methods and compositions useful for stimulating an immune response
|
|
WO2003008537A2
(en)
*
|
2001-04-06 |
2003-01-30 |
Mannkind Corporation |
Epitope sequences
|
|
US7414032B2
(en)
|
2001-06-25 |
2008-08-19 |
Immunofrontier, Inc. |
Vaccine comprising a polynucleotide encoding an antigen recognized by a CD4+ helper T-cell and a polynucleotide encoding a tumor specific or associated antigen recognized by a CD8+ CTL
|
|
WO2005035773A2
(en)
*
|
2003-10-08 |
2005-04-21 |
Sanofi Pasteur, Inc. |
Modified cea /b7 vector
|
|
CN1938044B
(zh)
|
2002-12-16 |
2011-12-28 |
全球免疫股份有限公司 |
用于免疫治疗的基于酵母的疫苗
|
|
CA2537931A1
(en)
*
|
2003-09-05 |
2005-03-24 |
Dennis Panicali |
Multi-antigen vectors for melanoma
|
|
JP4995575B2
(ja)
*
|
2003-11-12 |
2012-08-08 |
アメリカ合衆国 |
乳癌を処置および予防するためのシステム
|
|
AU2004289368B2
(en)
|
2003-11-12 |
2010-08-26 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Custom vectors for treating and preventing pancreatic cancer
|
|
WO2005068640A2
(en)
*
|
2003-12-23 |
2005-07-28 |
Aventis Pasteur, Inc. |
Modified ksa and uses thereof
|
|
US7785875B2
(en)
|
2004-07-03 |
2010-08-31 |
Mogam Biotechnology Research Institute |
Polynucleotide encoding HCV epitopes which can bind to various HLA supertypes, immunogenic composition comprising same and method of inducing an HCV-specific immune response using same
|
|
US20080112977A1
(en)
*
|
2004-07-03 |
2008-05-15 |
Mogam Biotechnology Research |
Supertype Epitopes, Oligonucleotides Coding The Same Which Induce Effective Ctl Response Against Hcv And The Use Thereof
|
|
ES2313807B1
(es)
*
|
2005-07-30 |
2009-12-23 |
Consejo Superior De Investigaciones Cientificas |
Vectores recombinantes basados en el virus vaccinia modificado de ankara (mva) como vacunas contra la leishmaniasis.
|
|
EP1792996A1
(en)
*
|
2005-12-01 |
2007-06-06 |
Consejo Superior de Investigaciones Cientificas |
Nucleic acid sequences encoding vaccines against Porcine reproductive and respiratory syndrome virus (PRRSV)
|
|
US8389282B2
(en)
*
|
2007-03-30 |
2013-03-05 |
Memorial Sloan-Kettering Cancer Center |
Constitutive expression of costimulatory ligands on adoptively transferred T lymphocytes
|
|
EP2170384B1
(en)
|
2007-07-02 |
2016-04-13 |
Etubics Corporation |
Methods and compositions for producing an adenovirus vector for use with multiple vaccinations
|
|
NZ584042A
(en)
*
|
2007-10-18 |
2012-09-28 |
Bn Immunotherapeutics Inc |
Use of mva to treat prostate cancer
|
|
US8475790B2
(en)
|
2008-10-06 |
2013-07-02 |
Bristol-Myers Squibb Company |
Combination of CD137 antibody and CTLA-4 antibody for the treatment of proliferative diseases
|
|
US8691502B2
(en)
|
2008-10-31 |
2014-04-08 |
Tremrx, Inc. |
T-cell vaccination with viral vectors via mechanical epidermal disruption
|
|
WO2010050913A1
(en)
*
|
2008-10-31 |
2010-05-06 |
The Brigham And Women's Hospital, Inc. |
Vaccination with poxvirus vectors via mechanical epidermal disruption
|
|
ES2660597T3
(es)
|
2009-04-17 |
2018-03-23 |
Globeimmune, Inc. |
Composiciones inmunoterápicas de combinación contra el cáncer y métodos
|
|
JP6122007B2
(ja)
|
2011-08-17 |
2017-04-26 |
グローブイミューン，インコーポレイテッド |
酵母−ｍｕｃ１免疫療法用組成物およびその使用
|
|
WO2014031178A1
(en)
|
2012-08-24 |
2014-02-27 |
Etubics Corporation |
Replication defective adenovirus vector in vaccination
|
|
EP3777870A1
(en)
|
2013-06-14 |
2021-02-17 |
Psioxus Therapeutics Limited |
A dosing regime and formulations for type b adenoviruses
|
|
SI3021859T1
(en)
|
2013-10-25 |
2018-04-30 |
Psioxus Therapeutics Limited |
Oncolytic adenoviruses equipped with heterologous genes
|
|
BR112016011866A2
(pt)
*
|
2013-11-28 |
2017-09-26 |
Bavarian Nordic As |
vetores de composições e métodos para induzir uma resposta imune potencializada usando vetores de poxvírus
|
|
JP5917626B2
(ja)
*
|
2014-07-28 |
2016-05-18 |
トレムアールエックス， インコーポレイテッド |
機械的表皮破壊を介したポックスウイルスベクターによるワクチン接種
|
|
CN113456812B
(zh)
|
2015-01-09 |
2024-08-20 |
埃图比克斯公司 |
用于联合免疫治疗的方法和组合物
|
|
JP2018502922A
(ja)
|
2015-01-09 |
2018-02-01 |
イーチュービクス コーポレイション |
エボラウイルスワクチン接種のための方法および組成物
|
|
US11149087B2
(en)
|
2015-04-20 |
2021-10-19 |
Etubics Corporation |
Methods and compositions for combination immunotherapy
|
|
KR102854512B1
(ko)
*
|
2015-04-30 |
2025-09-04 |
아카미스 바이오 리미티드 |
B7 단백질을 암호화하는 종양세포붕괴 아데노바이러스
|
|
KR20180108590A
(ko)
|
2015-12-17 |
2018-10-04 |
싸이오서스 테라퓨틱스 엘티디. |
항-tcr-복합체 항체 또는 단편을 암호화하는 바이러스
|
|
WO2017161360A2
(en)
*
|
2016-03-18 |
2017-09-21 |
Nant Holdings Ip, Llc |
Multimodal vector for dendritic cell infection
|
|
CA3025648A1
(en)
*
|
2016-05-27 |
2017-11-30 |
Etubics Corporation |
Neoepitope vaccine compositions and methods of use thereof
|
|
CN110214025B
(zh)
|
2016-08-29 |
2024-08-02 |
阿卡米斯生物公司 |
携带双特异性t细胞衔接器的腺病毒
|
|
GB201713765D0
(en)
|
2017-08-28 |
2017-10-11 |
Psioxus Therapeutics Ltd |
Modified adenovirus
|
|
KR20200144540A
(ko)
*
|
2018-03-06 |
2020-12-29 |
페프박스, 인코포레이티드 |
핵산 분자 및 그 사용 방법
|
|
US20210290708A1
(en)
|
2018-09-21 |
2021-09-23 |
Nantcell, Inc. |
Methods and compositions for modulating myeloid-derived suppressor cells
|
|
GB202010095D0
(en)
*
|
2020-07-01 |
2020-08-12 |
Tcer Ab |
Immunotherapy
|